Results: There were a total of 1,761,060 possible COVID-19 pa tients based on ICD-10 diagnostic…read moreterms and confirmatory lab re sults. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536). Within the ivermectin cohort, average age was 51.9+17.8 years, 43% were male, 60% had glucocorticoids and 1% required ventilator sup port. In the remdesivir cohort, average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids and 2% required ventila tor support. After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir (OR 0.308, 95% CI (0.198,0.479)), Risk Difference -5.224%, CI (-7.079%, -3.369%), p is less than 0.0001.
Conclusion: Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTS with large samples are required for defi nite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.
https://doi.org/10.1016/j.ijid.2021.12.096
PS05.05 (359)
Surveillance of Immunological Status after Vaccination by two Serological Assays based on SARS-CoV-2 Spike Protein
A. Fresco-Taboada ¹, M. Garcia-Duran ¹.*, C. Aira ¹,
L. López¹, P. Sastre ¹, L. Van der Hoek ², M. Van Gils ², P.J.M. Brouwer2, R.W. Sanders 2, B. Holzer ³, I. Zimpernik ³, E. López-Collazo 4. P. Muñoz 5, P. Rueda, C. Vela ¹
